Four Potential Vaccines in Development to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on the Company’s Horsepox Virus Vaccine Platform Potential Vaccine, TNX-801, in Development to Protect Against Smallpox and Monkeypox Based on Horsepox Virus Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for the Management of Fibromyalgia; Topline Results Expected First Quarter 2021 NEW YORK, May 12, 2020 (GLOBE NEWSWIR
May 12, 2020
· 14 min read